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pen accessAbstract Background: This study was designed to ﬁnd out the effective antiemetic drug for pre-
vention of postoperative nausea and vomiting in high risk emetogenic patients undergoing thyroid
surgery.
Patients and methods: One hundred twenty patients, ASA I, II, subjected to elective thyroid surgery
were enrolled in this study. Patients were randomly assigned, according to antiemetic prophylaxis,
into three groups, each consisted of 40 patients. Patients received 4 mg ondansetron plus 8 mg dexa-
methasone (Group II) i.v. or 2 mg midazolam plus 8 mg dexamethasone (Group III) i.v. or saline
(Group I) just after induction of anesthesia. Frequency of nausea, vomiting, the use of antiemetics,
the complete response (deﬁned as no PONV and no administration of rescue antiemetic drug) were
recorded at three time points (6 h, 12 h, 24 h) postoperatively.
Results: We found that ondansetron/dexamethasone or midazolam/dexamethasone signiﬁcantly
increased the complete response, compared with placebo, with an incidence of 90%, 85%, and
22.5%, respectively at 6 h, 90%, 87.5%, 25%, respectively, at 12 h and 95%, 92.5%, 47.5%, respec-
tively at 24 h postoperatively.m (A. El-Deeb).
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204 A. El-Deeb et al.Conclusion: We conclude that the prophylactic use of ondansetron/dexamethasone or midazolam/
dexamethasone, compared with placebo, was effective for reducing nausea and vomiting in patients
undergoing thyroid surgery. Midazolam/dexamethasone is preferred due to its cost relative to
ondansetron/dexamethasone.
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Nausea, vomiting and pain are the most important periopera-
tive concerns from the patients’ point of view. PONV can lead
to delayed discharge from postanaesthetic care unit (PACU)
and recovery room and readmission to hospital [1]. Previous
studies, has reported the average incidence of PONV to be
40–60% [2,3]. Thyroidectomy is associated with relatively high
incidences of PONV, ranging from 60% to 84% [4].
Postoperative nausea and vomiting are disagreeable com-
plication that can be effectively managed. The risk must be
suitably assessed and acted on accordingly [5].
Apfel’s score predicting postoperative nausea and vomiting
(PONV) in potentially high-risk patients considered four risk
factors: female gender, previous history of PONV or motion
sickness, non-smoking status and postoperative use of opioids
[6,7]. Sinclair score included, in addition to these factors, dura-
tion, type of anesthesia and surgery [8].
Several studies demonstrated that dexamethasone has a po-
tent antiemetic effect for the prophylaxis of PONV in a dose of
8–10 mg IV [9]. Also, midazolam has been reported to be a
good antiemetic in controlling postoperative nausea and vom-
iting [10]. The clinical efﬁcacy of anti-emetic combination of
different classes is better than single drug therapy [11].
So far, the use of antiemetic combination for prevention of
PONV in high risk emetogenic patients undergoing thyroid
surgery has not been studied .The aim of this study was to
investigate the efﬁcacy and cost of two anti emetic combina-
tions for the prevention of PONV in high risk group of surgical
patients. We postulated that the use of i.v. midazolam/dexa-
methasone would reduce PONV after thyroid surgery.
2. Patients and methods
After institutional ethical committee approval and written in-
formed consent, we studied 120 ASA (American society of
anesthetists) physical status I or II patients, undergoing gen-
eral anesthesia for elective thyroidectomy. Risk factors for
PONV include adult female gender, previous history of
PONV, history of motion sickness, non-smoking status, and
duration of surgery more than 1 h. Inclusion criteria include
patients with 3 or more risk factors. Exclusion criteria include
age less than 17 years or more than 60 years, smoking, and sur-
gery lasting less than 1 h and known allergy or previous ad-
verse reaction to any of the study drugs.
Patients were randomly allocated using computer-generated
code to receive 2 ml saline i.v. (Group I, n= 40), or ondanse-
tron 4 mg/plus dexamethasone 8 mg i.v. (Group II, n= 40)
or midazolam 2 mg plus dexamethasone 8 mg i.v. (Group III,
n= 40). All solutions were 5 ml volume, looked identical, pre-
pared by personnel blinded to the study and were given imme-
diately after the induction of anesthesia. After the placement of
standard monitors (ECG, non invasive arterial blood pressure,oxygen saturation), anesthesia was induced with i.v. propofol
(2–2.5 mg/kg), and fentanyl (1 lg/kg) and vecuronium 0.15
mg/kg to facilitate tracheal intubation. After intubation, anes-
thesia was maintained with 2–2.5% sevoﬂurane and 50% oxy-
gen in 50% air. Ventilation was mechanically controlled and
adjusted to keep an end-tidal concentration of carbon dioxide
30–40 mmHg throughout surgery. At the end of the operation,
i.v. atropine (0.02 mg/kg) and neostigmine (0.04 mg/kg) were
administered for reversal of the residual paralysis, and the tra-
chea was extubated.
Postoperatively, Nausea and vomiting were evaluated every
3 h for 6 h then every 6 h up to 24 h by an observer who is
blinded to group assignment. Data were reported at three time
points (6 h, 12 h, 24 h). Retching (same as vomiting but without
expulsion of gastric contents) was considered vomiting. Nausea
was assessed using numerical scale (0 = no nausea; 10 = worst
imaginable nausea). An antiemetic ‘‘rescue’’ drug (1 mg gra-
nisetron intravenously) was administered in case severe nausea
(scale 4or more) or vomiting within the study period. The com-
plete response was deﬁned as no vomiting and no antiemetic
drug. Data were also collected regarding the duration of sur-
gery and side effects of dexamethasone, (e.g., wound infection),
midazolam (e.g., respiratory depression) and ondansetron (e.g.,
headache, dizziness) were reported. Sedation was assessed with
modiﬁed Ramsey sedation score (where 1 = Anxious, agitated
or restless, 2 = Co-operative, orientated, and tranquil, 3 =
semi sleep but responds to commands only, 4 = Brisk response
to a light glabellar tap, 5 = Sluggish response to a light glabel-
lar tap, 6 = No response to a light glabellar tap) [12] at 2 h
postoperatively.
Postoperative pain was assessed with a 10-cm visual analog
scale (0 = no pain to 10 = most severe pain) score. Postoper-
ative analgesia was achieved with IV paracetamol 500 mg
every 6 h. Diclofenac 75 mg IM is the rescue analgesic. Patient
satisfaction regarding antiemetic prophylaxis was evaluated
and recorded (10 point verbal numeric scoring system,
0 = not at all satisﬁed, 10 = fully satisﬁed).
3. Statistical analysis
The power analysis before the study showed that each group
should be composed of 35 patients for detecting a 50% relative
reduction in the incidence of postoperative nausea and/or
vomiting in high risk patients, with a conﬁdence interval of
95% (an error was set at 0.05). Forty patients were included
in each study group for more statistic validity. The statistical
analysis of data was performed using the SPSS for Windows
(version 11; SPSS Inc., Chicago, IL) statistical software pack-
age. Data are tested for normality using Kolmogorov–Smirnov
test. One way ANOVA test was performed to compare the
parametric values of the studied groups, followed by Post
Hoc test (Turkey’s test). The Kruskal–Wallis test was used
for the non-parametric analysis among the groups. P is
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tients (percentage) or median (range) or mean ± standard
deviation (SD).
4. Results
The three groups showed no signiﬁcant differences regarding
patient characteristics such as age, body mass index and dura-
tion of anesthesia (Table 1).
Nausea and vomiting were statistically signiﬁcant less in
groups II, III, compared to group I (placebo) up to 24 h.
The incidence of complete response in group I was 22.5% com-Table 1 Patient characteristics and duration of anesthesia.
Group I Group II Group III
Age (year) 32.1 ± 3.5 29.1 ± 3.4 30.2 ± 2.1
Body mass index 26 ± 1.2 27 ± 1.2 29 ± 1.3
Duration of anesthesia (min) 134 ± 4.2 132 ± 3.1 133 ± 5.1
Data are presented as mean ± standard deviation.
Table 2 Incidence of nausea and vomiting, rescue antiemetic
and complete response.
Group I Group II Group III
6 h postoperative
Nausea 27 (67.5%) 10 (25%)* 9 (22.5%)*
Vomiting 16 (45.5%) 4 (10%)* 5 (12.5%)*
Rescue antiemetic 21 (52.5%) 4 (10%)* 6 (15%)*
Complete response 9 (22.5%) 36 (90%)* 34 (85%)*
12 h postoperative
Nausea 22 (55%) 8 (20%)* 7 (17.5%)*
Vomiting 12 (30%) 3 (7.5%)* 4 (10%)*
Rescue antiemetic 10 (25%) 4 (10%)* 6 (15%)*
Complete response 10 (25%) 36 (90%)* 35 (87.5%)*
24 h postoperative
Nausea 10 (25%) 2 (5%)* 3 (7.5%)*
Vomiting 6 (15%) 1 (2.5%)* 1 (2.5%)*
Rescue antiemetic 9 (22.5%) 2 (5%)* 3 (7.5%)*
Complete response 19 (47.5%) 38 (95%)* 37 (92.5%)*
Values are presented as number of patient (percentage of study
group).
P value < 0.05 is signiﬁcant.
* Signiﬁcant when compared to group I.
Table 3 Perioperative data.
Group I Group II Group III
Sedation score 1 (1–1) 1 (1–1) 1 (1–2)
Side eﬀects
Dizziness 4 (10%) 3 (8.5%) 4 (10%)
Headache 6 (15%) 5 (12.5%) 5 (12.5%)
Satisfaction score 5 (2–6) 10 (8–10)* 10 (7–10)*
Values are presented as number of patient (percentage of study
group) or median (range).
P value <0.05 is signiﬁcant.
* Signiﬁcant when compared to group I.pared with 90%, 85 in group II and III, respectively, at 6 h,
whereas, it was 25%,90%, 87.5%, respectively, at 12 h and
47.5%, 95%, 92.5%, respectively, at 24 h postoperatively
(Table 2). Although complete response in group II was less
than that of Group III, it did not reach statistical signiﬁcance.
The antiemetic rescue and incidence of nausea and vomiting
were comparable between groups II, III during the study per-
iod (Table 2). No patient reported wound infection or respira-
tory depression in any group. Sedation score and other side
effects of the study drugs were comparable among the three
groups ( Table 3). Patient satisfaction with PONV control
was statistically signiﬁcant higher in groups II, III compared
with group I (Table 3).5. Discussion
PONV are among the most common side effects after surgery.
Increased incidence of PONV has been associated with many
factors including age, gender, obesity, prior history of motion
sickness or PONV, non-smoking, anesthetic techniques, surgi-
cal procedure and duration of surgery and the use of postop-
erative opioids [7,8]. Patients at high risk of postoperative
nausea and vomiting often receive more than one prophylactic
antiemetic drug [13]. In this study, patients with high risk fac-
tors were the target of this study. Other risk factors that can-
not be included in patient’s selection e.g. duration of surgery
and the anesthetic technique were comparable among the
study groups, So that the differences between the groups were
more likely to be caused by antiemetic prophylaxis.
Dexamethasone, ondansetron and midazolam have been
shown to be an effective antiemetic effect for the prophylaxis
of PONV [10,13]. The antiemetic effect of midazolam is due to
decrease in the dopaminergic neuronal activity and 5-HT3(5-hy-
droxy-tryptamine3) release by binding to the gamma-amino bu-
tyric acid (GABA) receptor [14]. Also, the mechanism of
antiemetic effect of dexamethasone is due to central inhibition
of prostaglandin synthesis and/or a decrease in serotonin turn-
over in the central nervous system [15]. Other antiemetics, such
as antihistamines (e.g., hydroxyzine), anticholinergics (e.g.,
scopolamine), and dopamine receptor antagonists (e.g., droper-
idol, metoclopramide) have undesirable side effects of excessive
sedation, tachycardia, drug mouth, dysphoria, and extra pyra-
midal symptoms [16,17].
The results of this study indicate that intravenous adminis-
tration of 4 mg ondansetron/8 mg dexamethasone or 2 mg
midazolam/8 mg dexamethasone during thyroid surgery re-
duced the incidence of PONV and improved the patient satis-
faction in high risk emetogenic patients.
This study showed that the complete response (the primary
outcome) at 24 h postoperatively in controlled patients (pla-
cebo) undergoing thyroid surgery was 47.5%. Wang et al.
[9], reported higher incidence (65%) which can be explained
by the type of patients. As patients included in this study are
at high risk of PONV. Also, patients in the placebo group
showed a high incidence of nausea at 6 h, 12 h, 24 h postoper-
atively (67.5%, 55%, 25% respectively)and of vomiting (45%,
30%, 15% respectively). This was in accord with recent clinical
study evaluating antiemetic prophylaxis in thyroid [18].
Administration of i.v 4 mg ondansetron/8 mg dexametha-
sone or 2 mg midazolam/8 mg dexamethasone resulted in in-
crease in the complete response at 24 h to 95%, 92.5%,
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89%) with 5, 10 mg dexamethasone which can be attributed
to the use of antiemetic combination in this study.
Our results demonstrated that ondansetron/dexamethasone
or midazolam/dexamethasone was effective in decreasing the
incidence of PONV from 69% to 44% during the 24 h after
surgery, which is comparable with the previous reports of
ondansetron use for the prevention of PONV [19,20,2]. Single
intravenous 8 mg dexamethasone, in this study, was not asso-
ciated with side effects. In accord with our results, a compar-
ative study of different antiemetic after acute abdominal
surgery showed similar results [21].
This study showed that 4 mg ondansetron/8 mg dexameth-
asone or 2 mg midazolam/8 mg dexamethasone was shown to
be comparable in preventing nausea and vomiting, and use of
antiemetic during the ﬁrst 24 h in high risk patients undergoing
thyroid surgery. However, midazolam/dexamethasone would
be better from the point of cost/effectiveness. Midazolam
2 mg and Dexamethasone 8 mg cost 7, 2.5 Egyptian bounds,
respectively, whereas ondansetron costs 26 Egyptian bounds
per 4 mg ampoule. Adverse events observed in our study were
similar among all three groups.
The limitation of this study was that we used only two drug
combination for PONV prophylaxis; further studies are
needed to investigate other possible drug or non pharmacolog-
ical combination.
In conclusion, ondansetron/dexamethasone or midazolam/
dexamethasone was equally effective in decreasing incidence of
PONV, need for rescue antiemetic, or patient satisfaction in
high-risk female patients during the ﬁrst 24 h after thyroid
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